PURPOSE To evaluate whether providing 17 alpha-hydroxyprogesterone caproate (17P) to high-risk pregnant women who have a history of preterm delivery in a Medicaid managed care population reduces the rate of neonatal intensive care unit (NICU) admissions, NICU length of stay, and associated costs. DESIGN A 2004-2005 longitudinal review of birth outcomes in 24 pregnant women with a history of p...

Cortisol, 11-deoxycorticosterone, progesterone, 17 alpha-hydroxy-progesterone, 17 alpha-hydroxy-20 beta-dihydroprogesterone, or a combination of the last 2 steroids, were injected into different groups of immature female Epinephelus. None of the steroids tested had significant effects on serum electrolyte level, and hepatosomatic and gonadosomatic indices. Serum glucose concentration was elevat...

Abstract Study question Is 17 alpha-hydroxyprogesterone caproate an adequate option to improve reproductive outcomes in patients with low serum progesterone (P4) level the day of frozen embryo transfer? Summary answer Patients P4<10ng/ml may benefit addition intramuscular 17alpha-hydroxyprogesterone injections, and have similar ongoing pregnancy rates than P4≥10ng/ml. What is known alrea...

OBJECTIVE To determine if gestational age of prior preterm delivery influences a woman's receipt of 17-hydroxyprogesterone caproate (17-OHP-C). METHODS Retrospective cohort of women eligible for 17-OHP-C at Duke Obstetrics Clinic were identified by medical record review. Sociodemographic and clinical characteristics were abstracted. Results. Of 104 eligible subjects, 82 (78.8%) were offered 1...